It is very uncertain whether higher changes food allergy ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
Higher showed no clear difference in asthma ‐ infant incidence compared with lower PUFA intake (low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes allergic rhinitis ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes all allergic disease ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes asthma ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether early and late (day 1 to 28 after birth) higher changes hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (very low certainty).
Late (seven days or more following birth) higher may leads to lower hyponatraemia (< 130 mmol/L) compared with lower sodium intake (low certainty).
It is very uncertain whether late (seven days or more following birth) higher changes hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (very low certainty).
Late (seven days or more following birth) higher may leads to lower postnatal growth failure (weight < 10th percentile) compared with lower sodium intake (low certainty).
It is very uncertain whether late (seven days or more following birth) higher changes necrotising enterocolitis compared with lower sodium intake (very low certainty).